Search Results

mTOR (Mammalian Target of Rapamycin) Inhibitors Strategic Research Report 2024: Expanding Applications Beyond Cancer Treatment - Global Forecast to 2030

• Source: Pharma & Healthcare Monitor Worldwide (Amman, Jordan), August 20, 2024 News, 4pp

Record details

Does an anti-ageing pill already exist?; Rapamycin has shown promise as a drug that not only can extend life by delaying the onset of ageing-related diseases, but also postpone the effects of normal ageing.

• Authors : By:Bill Gifford , Does an anti-ageing pill already ex

• Source: Business Times, The (Singapore), February 14, 2015 Health & Wellness, 5pp

Record details

Does an anti-ageing pill already exist?; Rapamycin has shown promise as a drug that not only can extend life by delaying the onset of ageing-related diseases, but also postpone the effects of normal ageing.

• Authors : By:Bill Gifford , Does an anti-ageing pill already ex

• Source: Business Times, The (Singapore), February 14, 2015 Health & Wellness, 5pp

Record details

Rapamycin Can Cause Diabetic-Like State

• Authors : By:Petra Rattue

• Source: Medical News Today (England), April 10, 2012 Transplants / Organ Donations, 3pp

Record details

Does an anti-aging pill already exist?

• Authors : By:Bill Gifford Bloomberg News

• Source: Daily Herald (Arlington Heights, IL), February 14, 2015 Business wire_, p. 1 11pp

Record details

Research and Markets: Global and Chinese Rapamycin (CAS 53123-88-9) Industry Research Report 2014

• Authors : By:Research and Markets; Laura Wood, Senior Manager;

• Source: Business Wire, December 15, 2014, 1pp

Record details

QTORIN Rapamycin Gets Positive Topline Results for Rare Skin Disease Treatment

• Authors : By:Emma Andrus, Assistant Editor

• Source: Dermatology Times (USA), March 13, 2023 News, 3pp

Record details

mTOR (Mammalian target of rapamycin) Inhibitors Market 2019 – Global Industry Analysis, Size, Share, Growth, Trends, Key Players and Forecast 2019 – 2023

• Authors : By:Sabmit Kumar

• Source: iCrowdNewswire (USA), October 2, 2019 News, 8pp

Record details

Palvella Therapeutics announces planned pivotal Phase 3 study design of QTORIN 3.9% rapamycin anhydrous gel (QTORIN rapamycin) for the treatment of microcystic lymphatic malformations and topline results from Phase 2b CODY study in Gorlin syndrome.

• Source: Chemical Business NewsBase (UK), July 20, 2023, 3pp

Record details

Palvella Therapeutics Announces Pipeline Update on QTORIN(TM) 3.9% Rapamycin Anhydrous Gel (QTORIN(TM) Rapamycin) for Serious, Rare Genetic Skin Diseases with No FDA-approved Therapies

• Source: GlobeNewswire (USA), February 21, 2023, 5pp

Record details